MARK4 and lung carcinoma: Finally, the correlation between miR‐515‐5p/MARK4 expression and the outcome of metastatic breast and lung cancer suggests the use of miR‐515‐5p and MARK4 as prognostic molecular biomarkers for metastatic cancer patients.